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Reply
We appreciate the comments from Drs. Bode and Simpson
regarding our report on simvastatin’s effect on skeletal muscle.
We agree that a crossover design would be a more optimal
approach. However, we did find that the case patients and control
individuals were appropriately and close to optimally matched
when the present design was applied.
The inherent “clinical” differences between case and control indi-
viduals as Drs. Bode and Simpson suggested are possible but in our
minds unlikely. In support for their contention, they cited a paper for
finding alterations in coenzyme Q10 concentrations in patients with
diabetes, but unfortunately the essential information of whether these
patients were being treated with statins is lacking (1).
We do not claim to have proven that a decrease in coenzyme
10 content is instrumental in the myalgia. Rather, we wrote that
he impaired oxidative phosphorylation capacity was a plausible
echanistic explanation for the muscle pain.
A study conducted in mice showed that treatment with a
ipophilic statin (atorvastatin) impaired mitochondrial activity
NADH oxidase activity) as well as ubiquinone content without an
ffect on mitochondrial density, compared with control mice (2).
This was reversed with coenzyme Q10 supplementation (2). This
tudy confirmed that the statin treatment itself had the negative
ffect on skeletal muscle (2), as we reported in our study (3).
owever, overall reports on the effects of coenzyme Q10 supple-
entation on myalgia are ambiguous (4,5), but none of these
tudies investigated coenzyme Q10 content in human skeletal
uscle.
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Issues Needing Clarification
Regarding Population
Characteristics in the Analysis
From the National Cardiovascular
Data Registry
We read with interest the paper by Baklanov et al. (1), but we
think that some issues need to be clarified regarding the population
characteristics of the Prevalence and Outcomes of Transradial
Percutaneous Coronary Intervention for ST-Segment Elevation
Myocardial Infarction: Analysis From the National Cardiovascular
Data Registry (2007 to 2011).
First, there is no information about sheath sizes used in the
study groups. One of the endpoints was bleeding, and overt
access site bleeding and retroperitoneal hemorrhage within 72 h
of percutaneous coronary intervention (PCI) were included in
the definition of bleeding. Doyle et al. (2) reported that using
sheath sizes 6-F was identified as a strong independent
predictor of major femoral bleeding. Trimarchi et al. (3)
eported that adopting a sheath size of 8-F or larger was
ndependently related to independent predictors of retroperito-
eal hematoma after PCI.
Second, the incidence of high-risk C-type coronary lesions was
ignificantly greater in the femoral access group compared with the
adial access group. Barbash et al. (4) concluded that a type-C
oronary lesion was an angiographic predictor of PCI failure for
T-segment elevation myocardial infarction. In addition, Wilen-
ky et al. (5) reported that PCI for complex lesions was associated
ith increased in-hospital mortality. When considering that PCI
uccess and mortality were defined as primary endpoints of the
tudy, results may be affected because of this difference between
roups.
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June 11, 2013:2391–6Finally, patients with renal failure receiving hemodialysis
were significantly more common in the femoral access group. It
is well-known that patients with renal failure have bleeding
disorders due to uremic platelet dysfunction (6). Skin bleeding
time is used for the evaluation of platelet dysfunction (7).
Dialysis may partially correct these defects, but cannot totally
eliminate them. The hemodialysis process itself may in fact
contribute to bleeding. Baklanov et al. (1) did not clarify
whether they evaluated bleeding disorders using skin bleeding
time and excluded this type of patient from the study popula-
tion. They used propensity score (PS) matching in the study.
Even though the PS can balance observed baseline covariates
between groups, they do nothing to balance unmeasured char-
acteristics and confounders. PS analyses have the limitation that
remaining unmeasured confounding may still be present. Ac-
cording to their paper, the PS did not include skin bleeding
time or any different method to identify the presence of a
bleeding disorder. Therefore, this situation may have affected
the results of the study.
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Reply
The letter by Dr. Yarlioglues and colleagues reflects the
challenges associated with interpreting analyses of large data
registries, such as the CathPCI Registry (1). From the very
beginning of the information era in cardiology, the greatestchallenges of data analysis were the frequency of changing
treatments, confusing terminology, and nonstandard defini-
tions. Recognizing these challenges, the American College of
Cardiology in 1987 set out to standardize percutaneous coro-
nary intervention (PCI)–related information (2). Data pertain-
ing to 100,000 PCI procedures are uploaded to the CathPCI
Registry every quarter, which underscores the importance of
selective approach to this process.
None of the variables that interest Dr. Yarliogues and
colleagues were included in the propensity scores because they
are not collected nor validated in the National Cardiovascular
Data Registry bleeding and mortality models. Because the
information regarding sheath size and “skin bleeding time” is
not included on CathPCI Registry data collection forms, we
cannot comment on the association between these variables and
patient outcomes. Importantly, renal failure, a marker for
platelet dysfunction, was reported and adjusted for in our
analysis.
Differences between clinical and procedural characteristics are
quite common when comparison groups are formed retrospec-
tively. Dr. Yarliogues and colleagues noted a 64% versus 66%
difference between C-type lesions in the radial and femoral access
groups. Clinically, this difference is not important. Similar differ-
ences are present in the proportion of patients with peripheral
vascular disease, a family history of coronary artery disease, and
other characteristics, all of which reach nominal statistical signif-
icance due to the size of the registry.
Our study accurately describes the prevalence of transradial PCI
in ST-segment elevation myocardial infarction and its association
with the outcomes. Moreover, the results of our study are consis-
tent with those of the recently published randomized trials
showing transradial primary PCI to be superior with respect to
bleeding and clinical outcomes (3). Therefore, although we appre-
ciate the thoughtful comments by Dr. Yarlioglues and colleagues
we believe that the data in our paper are robust and supported by
other studies.
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